Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2004 May 3;14(9):2245-8.

Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.

Author information

1
AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

Abstract

Exploration of SAR and optimisation of the imidazo[1,2-a]pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions of substitution, which allow modification of physical properties and offer the potential for in vivo optimisation.

PMID:
15081017
DOI:
10.1016/j.bmcl.2004.02.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center